Biomarker-driven drug development is widely used and has the potential to make drug discovery, development, and approval processes more efficient while improving patient outcomes. The data derived from biomarkers plays a key role in decision-making throughout the entire drug development pipeline, from drug mode of action, efficacy, and safety assessments to patient stratification and evaluation of clinical trial endpoints.

Mercodia offers comprehensive biomarker testing solutions, including large molecules, biosimilars, peptides, and oligonucleotides to support pharmaceutical and biotechnology companies in drug development. Understanding the specific context of use of a biomarker is essential for designing a cost- and time-effective bioanalytical strategy. Learn how to tailor your bioanalytical strategy to fit the study needs